Decreased production of erythropoietin (EPO) causes anemia in patients with chronic kidney disease, and recombinant human EPO is used to treat renal failure associated anemia. The liver, the main EPO-producing organ in utero, maintains the capacity to produce EPO in the adult but in insufficient quantities to restore hemoglobin levels to normal in patients with impaired renal function. Inhibition of prolyl-4-hydroxylase domain (PHD) proteins is known to cause an increase in EPO production through its effects on hypoxia inducible factor. Here, we utilized small interfering RNA (siRNA) targeting EGLN1, the gene encoding the PHD2 protein, to investigate the phenotypic consequences in nonhuman primates. A single, well-tolerated intravenous dose of an optimized EGLN1 siRNA encapsulated in a lipid nanoparticle formulation caused robust mRNA silencing in the liver, leading to increases in serum EPO and hemoglobin. The siRNA-induced erythropoiesis was dose-dependent and was sustained for at least 2 months. These data point to the potential for an RNA interference–based, liver-targeted therapeutic approach for the treatment of anemia.
Get full access to this article
View all access options for this article.
References
1.
KassebaumNJ, JasrasariaR, NaghaviM, WulfSK, JohnsN, LozanoR, ReganM, WeatherallD, ChouDP, et al. (2014). A systematic analysis of global anemia burden from 1990 to 2010. Blood, 123:615–624.
FandreyJ. (2004). Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol, 286:R977–R988.
4.
PaliegeA, RosenbergerC, BondkeA, SciesielskiL, ShinaA, HeymanSN, FlippinLA, ArendM, KlausSJ and BachmannS. (2010). Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int, 77:312–318.
5.
EckardtKU, PughCW, MeierM, TanCC, RatcliffePJ, and KurtzA. (1994). Production of erythropoietin by liver cells in vivo and in vitro. Ann N Y Acad Sci, 718:50–60.
6.
KapitsinouPP, LiuQ, UngerTL, RhaJ, DavidoffO, KeithB, EpsteinJA, MooresSL, Erickson-MillerCL and HaaseVH. (2010). Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood, 116:3039–3048.
7.
TanCC, EckardtKU, FirthJD, and RatcliffePJ. (1992). Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol, 263:F474–F481.
8.
SemenzaGL. (2009). Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda), 24:97–106.
9.
FrankeK, KaluckaJ, MamloukS, SinghRP, MuschterA, WeidemannA, IyengarV, JahnS, WieczorekK, et al. (2013). HIF-1alpha is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2alpha-induced excessive erythropoiesis. Blood, 121:1436–1445.
10.
GruberM, HuCJ, JohnsonRS, BrownEJ, KeithB, and SimonMC. (2007). Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A, 104:2301–2306.
ScortegagnaM, DingK, ZhangQ, OktayY, BennettMJ, BennettM, SheltonJM, RichardsonJA, MoeO, and GarciaJA. (2005). HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood, 105:3133–3140.
13.
FongGH and TakedaK. (2008). Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ, 15:635–641.
14.
KoivunenP, TiainenP, HyvarinenJ, WilliamsKE, SormunenR, KlausSJ, KivirikkoKI and MyllyharjuJ. (2007). An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. J Biol Chem, 282:30544–30552.
15.
OehmeF, EllinghausP, KolkhofP, SmithTJ, RamakrishnanS, HutterJ, SchrammM and FlammeI. (2002). Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun, 296:343–349.
16.
MazzoneM, DettoriD, Leite de OliveiraR, LogesS,, SchmidtT,, JonckxB, TianYM,, LanahanAA, PollardP, et al. (2009). Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell, 136:839–851.
17.
MinamishimaYA, MoslehiJ, BardeesyN, CullenD, BronsonRT and KaelinWGJr. (2008). Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood, 111:3236–3244.
18.
PercyMJ, ZhaoQ, FloresA, HarrisonC, LappinTR, MaxwellPH, McMullinMF and LeeFS. (2006). A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A, 103:654–9.
19.
PercyMJ, FurlowPW, BeerPA, LappinTR, McMullinMF and LeeFS. (2007). A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood, 110:2193–2196.
20.
TakedaK, CowanA and FongGH. (2007). Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation, 116:774–781.
21.
AragonesJ, SchneiderM, Van GeyteK, FraislP, DresselaersT, MazzoneM, DirkxR, ZacchignaS, LemieuxH, et al. (2008). Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet, 40:170–180.
22.
MinamishimaYA, MoslehiJ, PaderaRF, BronsonRT, Liao andR, KaelinWGJr. (2009). A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol, 29:5729–5741.
23.
TakedaK, AguilaHL, ParikhNS, LiX, LamotheK, DuanLJ, TakedaH, LeeFS, and FongGH. (2008). Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood, 111:3229–3235.
24.
EschbachJW. (2002). Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol, 13:1412–1414.
25.
JelkmannW. (2008). Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol, 141:287–297.
26.
McCulloughPA, BarnhartHX, InrigJK, ReddanD, SappS, Patel AKUD, SinghAK, SzczechLA and CaliffRM. (2013). Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol, 37:549–558.
27.
SinghAK, SzczechL, TangKL, BarnhartH, SappS, WolfsonM and ReddanD. (2006). Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med, 355:2085–2098.
28.
MinamishimaYA and KaelinWGJr. (2010). Reactivation of hepatic EPO synthesis in mice after PHD loss. Science, 329:407.
29.
QuerbesW, BogoradRL, MoslehiJ, WongJ, ChanAY, BulgakovaE, KuchimanchiS, AkincA, FitzgeraldK, KotelianskyV, et al. (2012). Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood, 120:1916–1922.
30.
AbramsMT, KoserML, SeitzerJ, WilliamsSC, DiPietroMA, WangW, ShawAW, MaoX, JadhavV, et al. (2010). Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther, 18:171–180.
31.
ZhangJ, PeiY, ZhangH, WangL, ArringtonL, ZhangY, GlassA and LeoneAM. (2013). Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance. Mol Pharm, 10:397–405.
32.
GindyME, LeoneMAM and CunninghamJJ. (2012). Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics. Expert Opin Drug Deliv, 9:171–182.
33.
HassimotoM, HaradaT and HaradaT. (2004). Changes in hematology, biochemical values, and restraint ECG of rhesus monkeys (Macaca mulatta) following 6-month laboratory acclimation. J Med Primatol, 33:175–186.
34.
PeiY, HancockPJ, ZhangH, BartzR, CherrinC, InnocentN, PomerantzCJ, SeitzerJ, KoserML, et al. (2010). Quantitative evaluation of siRNA delivery in vivo. RNA, 16:2553–2563.
35.
SempleSC, AkincA, ChenJ, SandhuAP, MuiBL, ChoCK, SahDW, StebbingD, CrosleyEJ, et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol, 28:172–176.
36.
WilsonRC and DoudnaJA. (2013). Molecular mechanisms of RNA interference. Annu Rev Biophys, 42:217–239.
37.
PakM, LopezMA, GabayanV, GanzT, and RiveraS. (2006). Suppression of hepcidin during anemia requires erythropoietic activity. Blood, 108:3730–3735.
38.
JelkmannW. (2007). Control of erythropoietin gene expression and its use in medicine. Methods Enzymol, 435:179–197.
39.
LiuQ, DavidoffO, NissK and HaaseVH. (2012). Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest, 122:4635–4644.
40.
YanL, ColandreaVJ, and HaleJJ. (2010). Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Pat, 20:1219–1245.
41.
MuchnikE and KaplanJ. (2011). HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs, 20:645–656.
42.
CoelhoT, AdamsD, SilvaA, LozeronP, HawkinsPN, MantT, PerezJ, ChiesaJ, WarringtonS, et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med, 369:819–829.
43.
TaberneroJ, ShapiroGI, LoRussoPM, CervantesA, SchwartzGK, WeissGJ, Paz-AresL, ChoDC, InfanteJR, et al. (2013). First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov, 3:406–417.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
